sharmasonali123

    Posts

    Europe Will Continue To Be The Most Lucrative Market For Human Milk Oligosaccharides Over 2027

    <p>Human milk oligosaccharides (HMO) helps in maintaining infant&rsquo;s gut microbiota as well as promotes the growth of healthy bacteria and reduce pathogens, preventing infections and others bacterial risks. In recent past, sales of infant nutrition products have increased to a significant extent owing to the continuously rising infant population across the globe. According to WHO, the total world population is estimated to increase by approximately one billion in the next 10 years and will reach 9.5 billion by 2050. Incidentally, demand has been relatively higher to the supply of infant nutrition products. Meanwhile, sales of infant formula are also surging in some of the Asian countries such as China and India, promoting the consumption of HMO alike.&nbsp; Future Market Insights&rsquo; latest report reveals that the global <a href="https://www.futuremarketinsights.com/reports/human-milk-oligosaccharides-market">human milk oligosaccharides market</a> is set to surpass a valuation of US$ 76 Mn, registering a CAGR of 14.6% between 2017 and 2027.&nbsp; This growth will be primarily orchestrated by the increasing application of HMO in infant nutrition products.</p><p>In 2017 and beyond, the human milk oligosaccharides market in Europe is anticipated to witness significant revenue growth. Towards the end of 2027, Europe is anticipated to account for over 49% value share of the global market. Manufacturers in Europe are filing claims for regulatory approvals and product safety certifications in order to use HMO for preparing infant formulas. In North America, the HMO market is currently valued at over US$ 6 Mn and holds the second spot in terms of market size after Europe.</p><p><strong>Request Report Sample @ <a href="https://www.futuremarketinsights.com/reports/sample/rep-gb-4252">https://www.futuremarketinsights.com/reports/sample/rep-gb-4252</a></strong></p><p>FMI&rsquo;s report, titled &ldquo;Human Milk Oligosaccharides Market Global Industry Analysis and Opportunity Assessment, 2017 &ndash; 2027&rdquo; also cites that demand for HMO is gaining traction due to a positive perception of its prebiotic properties that help maintain a healthy immune system in infants. In addition, manufacturers are focusing on increasing their production capacities in order to enhance production of HMOs such as 2&rsquo;-FL (2-fucosyllactose) that can be potentially used as an ingredient in functional food and beverages. zuChem Inc., Glycosyn LLC, Elicityl SA, Jennewein Biotechnologie GmbH, Glycom A/S, Dextra Laboratories Limited, Carbosynth Limited, Inbiose NV, ProZyme, Inc. are the leading companies operating in the global human milk oligosaccharides market.</p>>Key Excerpts of the Report Include:</p><ul><li><p>Among product type, fucosyllactose HMO currently accounts for the largest value share of the market followed by sialyllactose HMO.

    A New FMI Study on Automotive Gudgeon Pin Landscape: Over 55% Revenue Share Belongs to Tier 1 Players

    The approximately US$ 2.5 billion market for automotive gudgeon pin is poised for a moderate, just-under 5% yearly growth in the revenue, in 2019. A new study by Future Market Insights emphasizes the critical role of aftermarket in influencing the overall sales picture of automotive gudgeon landscape. The report also sheds lights on the significance of a growing trend involving green combustion engine technologies in shaping the competitive landscape of automotive gudgeon pin marketplace. Request Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5882 Aftermarket Reflects Noteworthy Potential in Terms of Sales Two-wheeler Parc Boosts Market Growth in Emerging Economies Dramatically fostering automotive production in major developing regions including Asia Pacific, Africa, and Latin America is projected to boost automotive gudgeon pin sales in OEMs segment. Passenger cars currently take up an approximate share of 50% in the total market value. Ask the Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-5882